Nathan Matthewson

Nathan Matthewson

Company: Asher Biotherapeutics Inc.

Job title: Cell Therapy Lead


Selective Cell Type Targeting Improves Anti-tumor Activity and Safety of Cytokines 3:30 pm

Asher Bio’s cis-targeting platform generates cell type selective immunomodulators Selective activation of CD8+ T cells by a CD8-targeted IL-2 results in enhanced anti-tumor activity and safety CAR-targeted IL-2 drives selective CAR-T cell expansion and improves anti-tumor activityRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.